Effect of Nanotechnology Structured Water Magnalife for the Prevention of Recurrent Urinary Tract Infections.

A Randomized, Double-blind, Placebo-controlled Clinical Study to Assess the Use of Nanotechnology Structured Water Magnalife for the Prevention of Recurrent Urinary Tract Infections.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04306731

Enrollment

437

Registered

2020-03-13

Start date

2014-09-20

Completion date

2017-04-21

Last updated

2020-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Urinary Tract Infection

Keywords

nanotechnology water, antibiotic prophylaxis, recurrent UTI.

Brief summary

This study investigates nanotechnology structured water magnalife in urology and to test its effects against lower urinary tract infections (UTI) in females.

Detailed description

This study represents the first time to use nanotechnology structured water magnalife in urology and to test its effects against lower urinary tract infections (UTI) in females. Urinary tract infection (UTI ) is the second most common bacterial infection, affecting women at a much higher frequency than men. There is a higher rate of recurrence of UTI, and a recurrent infection will follow 25-35% of initial UTI episodes within 3-6 months. Intermittent or prolonged low dose antibiotic therapy has been used to treat and prevent recurrent UTI. Emerging of resistance to antimicrobial agents, enormous economic burden, and the side effects of antibiotics have led to the search for an alternative non-antibiotic prophylaxis of recurrent UTI. Nanotechnology structured water is a new type of drinking water that has been prepared using different types of energy fields and electromagnetic fields to produce this structured water, which has new and different characteristics from the ordinary water. In the current study, the efficacy of nanotechnology structured water magnalife was compared with low-dose Trimethoprim and bottled drinking water for the prevention of recurrent UTI.

Interventions

DIETARY_SUPPLEMENTNanotechnology Structured water Magnalife

Nanotechnology Structured water Magnalife is drinking water that has been modified using nanotechnology to change the structuring of water molecules

DRUGTrimethoprim

Antibiotic

DIETARY_SUPPLEMENTOrdinary bottled drinking water

Placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

24 Years to 80 Years

Healthy volunteers

Inclusion criteria

* ≥ 2 (two or more than two) UTI in the last 6 months * ≥ 3 (three or more than three) UTI in the last 12 months

Exclusion criteria

* immunotherapy * radiotherapy * malignancy * steroids * chronic infections * chemotherapy * immunosuppressive drugs * anatomical abnormality of the urinary tract * surgical operation the urinary tract

Design outcomes

Primary

Measure	Time frame	Description
Recurrent Urinary Tract Infection	Twelve months	Urinalysis by GUE (\>10 white blood cells (WBC)/mm3 per high-power field (HPF) Urine culture (urinary pathogen of ≥105 colony-forming units (CFU) per mL)

Secondary

Measure	Time frame	Description
Time to first recurrent UTI	Twelve months	The time since the beginning of the study until the first recurrent UTI (days)

Countries

Iraq

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026